Novo Nordisk announced it will significantly reduce the list prices of its rapid-acting insulin Fiasp® and long-acting insulin Tresiba® in the United States starting January 1, 2026. The new wholesale acquisition costs (WAC) will reflect reductions of 75% for Fiasp® and 72.2% for Tresiba®, with the updated prices as follows:
Tresiba®:
- U-100 Vial: $94.29 (down from $338.95)
- U-100 Device: $141.43 (down from $508.43)
- U-200 Device: $169.71 (down from $610.11)
Fiasp®:
- Vial: $72.34 (down from $289.36)
- FlexTouch®: $139.71 (down from $558.83)
- PenFill®: $134.37 (down from $537.47)
- PumpCart®: $71.66 (down from $286.65)
These reductions align Fiasp® prices with NovoLog® and position Tresiba® 20% below its unbranded biologic equivalent, insulin degludec. Consequently, Novo Nordisk will discontinue its unbranded biologic insulin products by December 31, 2025, allowing more than a year for patients and healthcare providers to transition to alternatives.
Novo Nordisk remains committed to addressing affordability challenges in diabetes care. In 2023, nearly 1.5 million patients benefited from the company's NovoCare program, which offers financial support to individuals with or without insurance. For further details, visit NovoCare.com.
For more information, visit Novo Nordisk US or Reuters.